InDex Pharmaceuticals recently announced conclusions from its CONDUCT study, evaluating their TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. Congratulations to the positive results from the CONDUCT study. What are the next steps and when can we expect additional results? “Thank you! Thanks to the strong and unambiguous results from the … Continue reading Hey there Peter Zerhouni, CEO, InDex Pharmaceuticals